Barclays
KROS icon

Barclays’s Keros Therapeutics KROS Stock Holding History

Barclays’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$632K Buy
55,405
+5,701
+11% +$62.4K ﹤0.01% 3338
2026
Q2 		$532K Buy
49,704
+26,547
+115% +$296K ﹤0.01% 3180
2026
Q1 		$256K Sell
23,157
-51,569
-69% -$796K ﹤0.01% 3549
2025
Q4 		$1.52M Sell
74,726
-24,374
-25% -$428K ﹤0.01% 3124
2025
Q3 		$1.57M Sell
99,100
-22,030
-18% -$325K ﹤0.01% 3057
2025
Q2 		$1.62M Buy
121,130
+61,270
+102% +$827K ﹤0.01% 3018
2025
Q1 		$610K Sell
59,860
-47,682
-44% -$554K ﹤0.01% 3397
2024
Q4 		$1.7M Buy
107,542
+47,528
+79% +$2.47M ﹤0.01% 3020
2024
Q3 		$3.49M Buy
60,014
+35,022
+140% +$1.73M ﹤0.01% 2392
2024
Q2 		$1.14M Sell
24,992
-44,664
-64% -$2.4M ﹤0.01% 2523
2024
Q1 		$4.61M Sell
69,656
-190,104
-73% -$11.3M ﹤0.01% 1914
2023
Q4 		$10.3M Buy
259,760
+210,249
+425% +$6.59M ﹤0.01% 1494
2023
Q3 		$1.58M Buy
49,511
+11,118
+29% +$415K ﹤0.01% 2031
2023
Q2 		$1.54M Buy
38,393
+9,047
+31% +$397K ﹤0.01% 2052
2023
Q1 		$1.25M Sell
29,346
-8,589
-23% -$434K ﹤0.01% 2562
2022
Q4 		$1.82M Sell
37,935
-59,640
-61% -$2.79M ﹤0.01% 2320
2022
Q3 		$3.67M Buy
97,575
+63,658
+188% +$2.21M ﹤0.01% 1356
2022
Q2 		$936K Buy
33,917
+21,197
+167% +$930K ﹤0.01% 2420
2022
Q1 		$691K Buy
+12,720
New +$653K ﹤0.01% 2671

Other funds holding KROS

Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
IEQ Capital
IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return

Barclays's KROS Position: Q3 2026 in Review

Barclays increased its Keros Therapeutics (KROS) stake by 11% in Q3 2026, buying an estimated $62.4K and bringing the position to 55,405 shares worth $632K. The position accounts for ﹤0.01% of the portfolio, ranked #3338.

Barclays first reported a position in KROS in Q1 2022 and has held it in 19 quarters since. The position peaked at $10.3M in Q4 2023. 57 funds tracked by Wall St. Rank hold KROS as of Q3 2026.

  • Barclays held 55,405 shares of Keros Therapeutics worth $632K as of Q3 2026.
  • Barclays bought 5,701 Keros Therapeutics shares in Q3 2026, an estimated $62.4K.
  • Keros Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3338 holding.
  • Barclays first reported a position in Keros Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Keros Therapeutics position peaked at $10.3M in Q4 2023.
  • 57 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.